BiologicalDrug
Interleukin-12 clinical trials
Also written Ro 24-7472, rhIL-12 and Edodekin alfa.
- studies test it
- 45
- open now
- 0
- in phase 3
- 0
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 1997 (7)
| Year | Studies |
|---|---|
| 1997 | 7 |
| 1998 | 7 |
| 1999 | 6 |
| 2000 | 2 |
| 2001 | 6 |
| 2002 | 3 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 23
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 43
National Cancer Institute (NCI) (19) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Neumedicines Inc. (2) · University of Southern California (2) · University of Chicago (2) · Eastern Cooperative Oncology Group (2) · Beth Israel Deaconess Medical Center (2) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Aldesleukin (3) · GP-100 antigen (2) · MART-1 Antigen (2) · Rituximab (2) · Trastuzumab (2) · Paclitaxel (2) · Pembrolizumab (1) · Cetuximab (1)
Studies
Open first, then newest update. How each study uses Interleukin-12 is read from its arms, and is right about nine times in ten.
Testing it · 45
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03030378Written as Edodekin alfa
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01468896Written as Edodekin alfa
- A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)Active, not recruitingPhase 1University Health Network, TorontoNCT02483312Written as IL-12
- Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00019188Written as interleukin-12
- Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01266616Written as IL-12
- Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00005779Written as Interleukin-12
- A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000857Written as Interleukin-12
- Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02431767Written as Interleukin-12 (IL-12) DNA adjuvant
- Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00528489Written as IL-12
- Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.Status unknownPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04388033Written as Interleukin-12
- NM-IL-12 (rHuIL-12) in Subjects With Open Surgical WoundsCompletedPhase 2Neumedicines Inc.NCT02544061Written as NM-IL-12
- Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12TerminatedPhase 1/2Beth Israel Deaconess Medical CenterNCT00622401Written as Interleukin-12
- Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck CancerCompletedPhase 1/2Dana-Farber Cancer InstituteNCT00004070Written as IL-12
- Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS PatientsTerminatedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00057486Written as IL-12
- Treatment of Chronic Cryptosporidiosis in AIDS PatientsTerminatedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00001128Written as Interleukin-12
- Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic MelanomaTerminatedPhase 2National Cancer Institute (NCI)NCT01307618Written as Recombinant Interleukin-12
- NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage ChemotherapyStatus unknownPhase 2Neumedicines Inc.NCT02544724Written as NM-IL-12
- Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00004893Written as recombinant interleukin-12
- Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedPhase 2National Cancer Institute (NCI)NCT00003210Written as recombinant interleukin-12
- Interleukin-12 in Treating Patients With Hematologic Cancers or Solid TumorsCompletedPhase 1Indiana University School of MedicineNCT00003107Written as recombinant interleukin-12
See all 45 studies that test Interleukin-12 →
As the comparator · 1 — what is tested is compared with Interleukin-12
Codes
What other systems call Interleukin-12 · ClinicalTrials.gg INT008638
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D018664 | Interleukin-12 | One source ClinicalTrials.gov |
| RxNorm | 1371906 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.